Fulgent Genetics, Inc.

Fulgent is a technology-based company operating a laboratory services business and a therapeutic development business. Its laboratory services business provides technical laboratory and testing services, along with professional interpretation of laboratory results by licensed physicians. The therapeutic development business focuses on creating product candidates for various cancers using a nanoencapsulation and targeted therapy platform. This platform aims to enhance the therapeutic window and pharmacokinetic profile of both new and existing cancer drugs. Founded in 2011, Fulgent offers and develops diagnostic and genetic tests and laboratory services. The company's laboratory services include comprehensive anatomic pathology testing, covering gastrointestinal, dermatopathology, urologic, breast, neuropathology, and hematopathology. These services are supported by CLIA-licensed laboratories in the United States. Fulgent has also invested in digital pathology using AI technology to digitize specimen slides. The company also provides precision diagnostics testing services, including next-generation sequencing (NGS) tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and other disease subtypes. Specialized oncology services are part of precision diagnostics, utilizing technologies such as flow cytometry, cytogenetic analysis, fluorescence in-situ (FISH), immunohistochemistry, molecular genetics, NGS, and consultations in hematopathology and surgical pathology. Additionally, Fulgent offers testing services and licensing to pharmaceutical or biotech companies, contract research organizations (CROs), or sponsored testing programs, referred to as BioPharma services.